Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Immuneering reported a 17.3-month median overall survival in its Phase 2a trial of atebimetinib plus chemotherapy for first-line metastatic pancreatic cancer. The safety profile was favorable, with only anemia and neutropenia observed as Grade 3+ treatment-related adverse events in ≥10% of patients, both attributed to chemotherapy.
Key figures
- Drug Name
- atebimetinib (IMM-1-104)
- Phase Of Trial
- Phase 2a
- Patient count
- 55
- Median os months
- 17.3
- Grade 3 plus adverse events
- anemia (16%), neutropenia (18%)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.